-
Sector Analysis
China Contract Manufacturing Market Outlook – Trends, Ambitions, Key Players, Investment and Value Chain
There is an increasing reliance on contract manufacturing and development services due to the growing regulatory complexity surrounding drug production and development. China has been focusing on establishing volume and enhancing capabilities for innovative high-value drug production. This will enable the Chinese pharma manufacturers to compete with US and European equivalents in terms of obtaining contracts for lucrative treatments such as gene and cell therapies. China is also upgrading its manufacturing capabilities, boosting innovation, and strengthening its position in a...
-
Product Insights
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is a condition that affects many different parts of the body and occurs almost exclusively in males. Signs and symptoms include claw-like hands, protruding tongue, changing facial features, including thickening of the lips, tongue and nostrils and delayed development. Treatment includes bone marrow transplantation, enzyme therapy and gene therapy. The Mucopolysaccharidosis type II (MPS II) (Hunter Syndrome) pipeline market research report provides comprehensive information on the therapeutics under development for Mucopolysaccharidosis...
-
Product Insights
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Mucopolysaccharidosis type III (MPS III) is also known as Sanfilippo syndrome. It is an inherited metabolic disease caused by the absence or malfunctioning of certain enzymes needed to break down molecules called glycosaminoglycans (GAG). Symptoms include seizures, hyperactivity, liver and spleen enlargement, severe diarrhea or constipation, and enlargement of tonsils and adenoids. Treatment includes enzyme replacement therapy (ERT). The MPS III pipeline market research report provides comprehensive information on the therapeutics under development for MPS III, complete with analysis by...
-
Track & Monitor
Innovation in Pharmaceuticals: HIV peptides
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s HIV peptides segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based on...
-
Track & Monitor
Innovation in Pharmaceuticals: Adeno-associated virus vectors
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Adeno-associated virus vectors segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based...
-
Track & Monitor
Innovation in Pharmaceuticals: rtRNA virus peptides
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s rtRNA virus peptides segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based...
-
Track & Monitor
Innovation in Pharmaceuticals: Transcription factors for AAV
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Transcription factors for AAV segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MUMO-1
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry MUMO-1 Drug Details MUMO-1 is under development for the treatment of pain related diseases....
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – EGT-101
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry EGT-101 Drug Details EGT-101 is under development for the treatment of Sanfilippo syndrome type...
-
Product Insights
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
N-Sulphoglucosamine Sulphohydrolase is an enzyme encoded by the SGSH gene. This enzyme is involved in the lysosomal degradation of heparan sulfate. Mutations in this gene are associated with Sanfilippo syndrome A, one type of the lysosomal storage disease mucopolysaccaridosis III. The N-Sulphoglucosamine Sulphohydrolase - Drugs in Development research report provides a comprehensive overview on the therapeutics under development for N-Sulphoglucosamine Sulphohydrolase, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule...